Nanomedicine based approaches for the delivery of siRNA in cancer

Small interfering RNA (siRNA) technology holds great promise as a therapeutic intervention for targeted gene silencing in cancer and other diseases. However, in vivo systemic delivery of siRNA‐based therapeutics to tumour tissues/cells remains a challenge. The major limitations against the use of siRNA as a therapeutic tool are its degradation by serum nucleases, poor cellular uptake and rapid renal clearance following systemic administration. Several siRNA‐based loco‐regional therapeutics are already in clinical trials. Further development of siRNAs for anti‐cancer therapy depends on the development of safe and effective nanocarriers for systemic administration. To overcome these hurdles, nuclease‐resistant chemically modified siRNAs and variety of synthetic and natural biodegradable lipids and polymers have been developed to systemically deliver siRNA with different efficacy and safety profiles. Cationic liposomes have emerged as one of the most attractive carriers because of their ability to form complexes with negatively charged siRNA and high in vitro transfection efficiency. However, their effectiveness as potential therapeutic carriers is limited by potential for pulmonary toxicity. Recently, our laboratories described the use of neutral 1,2‐dioleoyl‐sn‐glycero‐3‐phosphatidylcholine based nanoliposomes in murine tumour models. We found this approach to be safe and 10‐ and 30‐fold more effective than cationic liposomes and naked siRNA, respectively, for systemic delivery of siRNA into tumour tissues. Here, we review potential approaches for systemic delivery of siRNA for cancer therapy.

[1]  Anil K Sood,et al.  Therapeutic EphA2 gene targeting in vivo using neutral liposomal small interfering RNA delivery. , 2005, Cancer research.

[2]  E. Fattal,et al.  Ocular delivery of nucleic acids: antisense oligonucleotides, aptamers and siRNA. , 2006, Advanced drug delivery reviews.

[3]  Shubiao Zhang,et al.  Toxicity of cationic lipids and cationic polymers in gene delivery. , 2006, Journal of controlled release : official journal of the Controlled Release Society.

[4]  T. Ochiya,et al.  Efficient delivery of small interfering RNA to bone-metastatic tumors by using atelocollagen in vivo. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[5]  T. Wu,et al.  Prospects of RNA interference therapy for cancer , 2006, Gene Therapy.

[6]  S. Hammond,et al.  An RNA-directed nuclease mediates post-transcriptional gene silencing in Drosophila cells , 2000, Nature.

[7]  T. Park,et al.  Comparative evaluation of target-specific GFP gene silencing efficiencies for antisense ODN, synthetic siRNA, and siRNA plasmid complexed with PEI-PEG-FOL conjugate. , 2006, Bioconjugate chemistry.

[8]  L. Ellis,et al.  Therapeutic targeting of neuropilin-2 on colorectal carcinoma cells implanted in the murine liver. , 2008, Journal of the National Cancer Institute.

[9]  Liz Y. Han,et al.  Focal Adhesion Kinase Targeting Using In vivo Short Interfering RNA Delivery in Neutral Liposomes for Ovarian Carcinoma Therapy , 2006, Clinical Cancer Research.

[10]  Matthias John,et al.  RNAi-mediated gene silencing in non-human primates , 2006, Nature.

[11]  M. Ogris,et al.  Induction of apoptosis in murine neuroblastoma by systemic delivery of transferrin-shielded siRNA polyplexes for downregulation of Ran. , 2008, Oligonucleotides.

[12]  Y. Maitani,et al.  Folate-linked lipid-based nanoparticles for synthetic siRNA delivery in KB tumor xenografts. , 2008, European journal of pharmaceutics and biopharmaceutics : official journal of Arbeitsgemeinschaft fur Pharmazeutische Verfahrenstechnik e.V.

[13]  H. Maeda.  The enhanced permeability and retention (EPR) effect in tumor vasculature: the key role of tumor-selective macromolecular drug targeting. , 2001, Advances in enzyme regulation.

[14]  A. Sood,et al.  Nuclear Factor-κB p65/relA Silencing Induces Apoptosis and Increases Gemcitabine Effectiveness in a Subset of Pancreatic Cancer Cells , 2008, Clinical Cancer Research.

[15]  Matthias John,et al.  Therapeutic silencing of an endogenous gene by systemic administration of modified siRNAs , 2004, Nature.

[16]  T. Rana,et al.  siRNA function in RNAi: a chemical modification analysis. , 2003, RNA.

[17]  A. Sood,et al.  Targeting melanoma growth and metastasis with systemic delivery of liposome-incorporated protease-activated receptor-1 small interfering RNA. , 2008, Cancer research.

[18]  Shan Jiang,et al.  Quantum-dot based nanoparticles for targeted silencing of HER2/neu gene via RNA interference. , 2007, Biomaterials.

[19]  K. Yagi.  [Cationic liposomes]. , 1995, Tanpakushitsu kakusan koso. Protein, nucleic acid, enzyme.

[20]  Andrew D. Miller,et al.  Lipidic carriers of siRNA: differences in the formulation, cellular uptake, and delivery with plasmid DNA. , 2004, Biochemistry.

[21]  Yang Wang,et al.  Antitumor activity of poly(ethylene glycol)-camptothecin conjugate: the inhibition of tumor growth in vivo. , 2005, Journal of controlled release : official journal of the Controlled Release Society.

[22]  T. Park,et al.  Local and systemic delivery of VEGF siRNA using polyelectrolyte complex micelles for effective treatment of cancer. , 2008, Journal of controlled release : official journal of the Controlled Release Society.

[23]  Leiming Li,et al.  Overcoming obstacles to develop effective and safe siRNA therapeutics. , 2009, Expert opinion on biological therapy.

[24]  A. Fire,et al.  Potent and specific genetic interference by double-stranded RNA in Caenorhabditis elegans , 1998, Nature.

[25]  Jinwoo Cheon,et al.  All-in-one target-cell-specific magnetic nanoparticles for simultaneous molecular imaging and siRNA delivery. , 2009, Angewandte Chemie.

[26]  G. Bazan,et al.  SNP detection using peptide nucleic acid probes and conjugated polymers: applications in neurodegenerative disease identification. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[27]  F. Fan,et al.  Therapeutic targeting of Id2 reduces growth of human colorectal carcinoma in the murine liver , 2008, Oncogene.

[28]  J. G. Patton,et al.  siRNA therapeutics: big potential from small RNAs , 2005, Gene Therapy.

[29]  Douglas D Boyd,et al.  The previously undescribed ZKSCAN3 (ZNF306) is a novel "driver" of colorectal cancer progression. , 2008, Cancer research.

[30]  N. Kosaka,et al.  Atelocollagen-mediated synthetic small interfering RNA delivery for effective gene silencing in vitro and in vivo. , 2004, Nucleic acids research.

[31]  A. Sood,et al.  Strategies for in vivo siRNA delivery in cancer. , 2008, Mini reviews in medicinal chemistry.

[32]  Y. Rojanasakul,et al.  Oxygen Radical-Mediated Pulmonary Toxicity Induced by Some Cationic Liposomes , 2000, Pharmaceutical Research.

[33]  S. Barik,et al.  Inhibition of respiratory viruses by nasally administered siRNA , 2005, Nature Medicine.

[34]  Mark E. Davis,et al.  Administration in non-human primates of escalating intravenous doses of targeted nanoparticles containing ribonucleotide reductase subunit M2 siRNA , 2007, Proceedings of the National Academy of Sciences.

[35]  P. Low,et al.  Folate receptor alpha as a tumor target in epithelial ovarian cancer. , 2008, Gynecologic oncology.

[36]  C. Miller,et al.  Liposome-cell interactions in vitro: effect of liposome surface charge on the binding and endocytosis of conventional and sterically stabilized liposomes. , 1998, Biochemistry.

[37]  Thomas Tuschl,et al.  Sequence, chemical, and structural variation of small interfering RNAs and short hairpin RNAs and the effect on mammalian gene silencing. , 2003, Antisense & nucleic acid drug development.

[38]  M. Stoffel,et al.  Mechanisms and optimization of in vivo delivery of lipophilic siRNAs , 2007, Nature Biotechnology.

[39]  John W. Park,et al.  Development of anti-p185HER2 immunoliposomes for cancer therapy. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[40]  Liz Y. Han,et al.  Effect of interleukin-8 gene silencing with liposome-encapsulated small interfering RNA on ovarian cancer cell growth. , 2008, Journal of the National Cancer Institute.

[41]  Jan-Fang Cheng,et al.  Dicer, Drosha, and outcomes in patients with ovarian cancer. , 2008, The New England journal of medicine.

[42]  P. Opolon,et al.  Intravenous delivery of anti-RhoA small interfering RNA loaded in nanoparticles of chitosan in mice: safety and efficacy in xenografted aggressive breast cancer. , 2006, Human gene therapy.

[43]  G. Hannon,et al.  Unlocking the potential of the human genome with RNA interference , 2004, Nature.

[44]  Jinwoo Cheon,et al.  Artificially engineered magnetic nanoparticles for ultra-sensitive molecular imaging , 2007, Nature Medicine.

[45]  Kenneth A Howard,et al.  RNA interference in vitro and in vivo using a novel chitosan/siRNA nanoparticle system. , 2006, Molecular therapy : the journal of the American Society of Gene Therapy.

[46]  Yuhan Lee,et al.  Cationic solid lipid nanoparticles reconstituted from low density lipoprotein components for delivery of siRNA. , 2008, Molecular pharmaceutics.

[47]  A. Gewirtz.  On future's doorstep: RNA interference and the pharmacopeia of tomorrow. , 2007, The Journal of clinical investigation.

[48]  Robert J. Lee,et al.  Folate receptor-targeted liposomes as possible delivery vehicles for boron neutron capture therapy. , 2003, Anticancer research.

[49]  Y. L. Chen,et al.  [Focal adhesion kinase]. , 1999, Sheng li ke xue jin zhan [Progress in physiology].

[50]  T. Tuschl,et al.  Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells , 2001, Nature.

[51]  A. C. Hunter.  Molecular hurdles in polyfectin design and mechanistic background to polycation induced cytotoxicity. , 2006, Advanced drug delivery reviews.

[52]  M. Manoharan,et al.  RNAi therapeutics: a potential new class of pharmaceutical drugs , 2006, Nature chemical biology.